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1988; JCO 6: 239-252, 1998) to prognostic factors that had been prospectively identified in the
previous trials (Int J Radiation One Bioi Phys 11: 23-30, 1985; Blood 73: 47-56, 1989), together with
response-related indicators (JCO 6: 596-602, 1988; Am J Hematol 37: 253-257, 1991; Ann Intern
Med.114: 361-365,1991).
In favourable patients, the extension of this strategy in the H6F trial allowed to spare them not only
the adjuvant chemotherapy (CT) but also laparotomy, establishing subtotal nodal irradiation (STNI) as
a new standard in clinically staged patients (ASH 1992; JCO 11: 2258-2272, 1993). In the subsequent
trials (H7F, H8F), brief combined non-toxic CT regimens with radiotherapy restricted only to the
involved-field (IF RT) provided superior freedom from progression (FFP) and at least comparable
overall survivals (OS) to(S) TN!.
In unfavourable patients, in the H5U trial, combined CT/RT modalities, preferably with an
adriamycin-containing regimen, provided better results than TN!. In the subsequent H7U and H8U
yrial, treatment adjustments balanced the respective intensitiesof CT and RT: treatment de escalation
proved dangerous.
In advanced stage disease, an earlier trial suggested that early response could be used to adapt
treatment modality and length (JCO 6: 596-602, 1988; JCO 12: 279-287, 1994). In the subsequent
trial, this observation has been successfully utilized for the early salvage of relapses (Ann Oneal 2: 63-
66, 1991) or poor responders(Ann Oncol, 1997) and the important question of adjuvant RT is being
investigated in a randomised way.
Underlying all HD trials, two basic concerns sustain the EORTC strategy, that encompass all
patients with HD. One is the need for permanent and prospective assessment of prognostic factors,
with which treatment continuously interacts; in this respect a continuum may exist between "localised"
and "advanced" HD. The other is aiming at the best possible treatment intensity adaptation to patient's
requirements for the sake of sparing short and long- term toxicities including those measured by
function and Quality of Life impairments. Combined modalities, including intensive ones, may remain
the best options for these tasks. The role of RT may persist in all patients categories, and that of
immunotherapy may develop, in parallel to the better understanding of HD natural history.
Working together with newly cooperating countries, like Poland, will allow a markedly better
understanding of early and late treatment effects, conditions for continuing to improve the care for our
patients.
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With conventional therapy, follicular Iymphona remains incurable for most patients. An experimental
approach is therefore justified.
Recognition of the association between follicular Iymphona and the (14;18) translocation and the
possibility of detecting residual disease at the molecular level using the polymerase chain reaction
(PCR), have led to the concept of 'molecular remission'.
Several new approaches, some of which have been reported to result in 'molecular remission' ego
the chimaeric antibody antti-CD20 and the combination Fludarabine, Mitoxantrone and
Dexamethasone are currently being evaluated at SBH. These and other treatment options, including
high dose treatment (Cyclophosphamide + total body irradiation) supported by autologous
haemopoietic progenitor cells, radio-labelled anti-CD20 and the nonmyeloablative regimen comprising
Fladarabine and Cyclophosphamide supported by allogeneic bone marrow transplantation will be
discussed.
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